

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

2022 THIRD QUARTERLY REPORT

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) to provide shareholders of the Company and the public with the updated financial information of the Company. This announcement is also published on the website of the Shanghai Stock Exchange simultaneously.

The unaudited results (the “**Third Quarterly Report**”) of the Group for the nine months ended 30 September 2022 are provided. The financial information contained in the Third Quarterly Report was prepared in accordance with the Chinese Accounting Standards for Business Enterprises (“**CASs**”), and consists accounting data which has not been audited. Potential investors and shareholders of the Company are advised to pay attention to the underlying investment risks.

The Third Quarterly Report is written in both Chinese and English. In the case of any discrepancies, the Chinese version of the Third Quarterly Report shall prevail.

By order of the Board

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Chairman

Shi Wenling

Beijing, the PRC, 26 October 2022

As at the date of this announcement, the executive Directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun, Mr. Xie Feng Bao and Ms. Shi Wenling; the non-executive Director of the Company is Mr. Wang Xin; and the independent non-executive Directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.

* For identification purposes only

Stock Code:688236

Stock Short Name: Chunli Medical

Beijing Chunlizhengda Medical Instruments Co., Ltd.

2022 Third Quarterly Report

The Board of Directors of the Company and all Directors undertake that this announcement contains no false record, misleading statement or material omission, and assume legal responsibility for the truthfulness, accuracy and completeness of its contents in accordance with law.

Important Notice:

The Board of Directors of the Company, the Board of Supervisors, the Directors, Supervisors, senior management warrant that the content of this quarterly report is true, accurate and complete and contains no false record, misleading statement or material omission, and jointly and severally assume legal responsibility for the content of this report.

The person in charge of the Company, the person in charge for accounting affairs of the Company and the person in charge of the accounting department (financial controller) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.

Whether the financial statements for the third quarter are audited?

☐Yes ☒No

Definitions

In this report, the following expressions shall, unless the context otherwise requires, have the following meanings:

“Current Reporting Period” or “Reporting Period” refers to the period commencing from 1 July 2022 and ending on 30 September 2022.

1. Key financial data

(A) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

Items	Current Reporting Period	Percentage change of the Current Reporting Period as compared to the corresponding period of last year (%)	From the beginning of the year to the end of the Reporting Period	Percentage change of the period from the beginning of the year to the end of the Reporting Period as compared to the corresponding period of last year (%)
Revenue	188,572,691.83	-20.02	759,964,308.26	5.79
Net profit attributable to the shareholders of the listed company	52,725,036.03	8.44	209,707,532.63	2.71
Net profit attributable to shareholders of listed company after deducting nonrecurring profit or loss	24,953,166.18	-46.80	181,615,047.03	-5.02
Net cash flows generated from operating activities	N/A	N/A	-76,368,941.72	-231.72
Basic earnings per share (yuan/share)	0.14	0.00	0.55	-6.78
Diluted earnings per share (yuan/share)	0.14	0.00	0.55	-6.78
Weighted average RONA (%)	2.04	Decrease by 1.80 percentage points	8.20	Decrease by 9.08 percentage points

2022 Third Quarterly Report

Total investments in research and development	32,724,564.79	5.72	105,014,400.73	61.11
Percentage of research and development investment to revenue (%)	17.35	Decrease by 4.22 percentage points	13.82	Decrease by 4.74 percentage points
	At the end of Current Reporting Period	At the end of last year		Percentage change at the end of this Reporting Period as compared to the end of last year (%)
Total assets	3,109,675,551.59	2,999,657,361.45		3.67
Owners' equity attributable to the shareholders of the listed company	2,621,688,166.70	2,469,077,386.48		6.18

Note: The “reporting period” refers to the three-month period from the beginning of this quarter to the end of this quarter, the same below.

(B) Non-recurring profit or loss items and amounts

Unit: Yuan Currency: RMB

Items	Amount for the Reporting Period	Amount for the period from the beginning of the year to the end of the Reporting Period	Description
Gain and loss from disposal of non-current assets		25,305.66	
Tax refund or exemption from ultra vires approval or without official approval document or received occasionally			

Government grants included in profit or loss for the current period other than those closely relating to the normal business of enterprises and subject to a fixed amount or quantity under certain standard and in compliance with national policies	19,580,021.54	22,193,041.45	
Capital utilization fee received from non-financial enterprises included in current profit or loss			
Investments of subsidiaries, associates and joint ventures in which the investment cost was less than the profit at fair value of identifiable net assets of the investees at the time of acquisition			
Gain or loss on exchange of non-monetary assets			
Gain or loss on entrusted investments or assets under management			
Provision for impairment on assets due to force majeure events, such as natural disasters			

Gain or loss on debt restructuring			
Corporate restructuring costs, such as staff resettlement expenses, consolidated charges, etc.			
Gain or loss on transactions at unfair trading prices over their fair value			
Net gains or losses of subsidiaries for the current period from the beginning of the period to the date of consolidation arising from business consolidation under common control			
Gain or loss from other contingencies which are not related to the Company's normal operations			
Gain or loss on changes in fair value of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities and derivative financial liabilities, and	13,100,561.66	13,100,561.66	

investment income from disposal of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities, derivative financial liabilities and other debt investments, except for effective hedging transactions that are related to the Company's normal operation			
Reversal of the impairment provision for receivables and contract assets under independent impairment test			
Gain or loss on entrusted loans			
Gain or loss arising from changes in fair value of investment properties under fair value method on subsequent measurement			
Effect of one-off adjustment to current profit or loss according to the requirements of laws and regulations on tax and accounting on			

current profit or loss			
Custody fee income from custody operations			
Other non-operating income and expenses apart from the aforesaid items	-10,010.13	-2,270,245.28	
Other gain or loss items conforming to the definition of non-recurring gains or losses			
Less : Effect of income tax	4,898,703.22	4,956,177.89	
Impact of minority interests (after tax)			
Total	27,771,869.85	28,092,485.60	

Explanations on defining the non-recurring gain or loss items set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public - Non-Recurring Gains or Losses as recurring gain or loss items

☐Applicable ☒Not applicable

(C) Description and reasons for the changes in key accounting data and financial indicators

☒Applicable ☐Not applicable

Items	Percentage change (%)	Main cause
Research and development expenses - from the beginning of the year to the end of the Reporting Period	61.11	The Company emphasized on the research and development of new products, new technology and new production skills, increased investment in research and development continuously, rapidly solved the pressure on sales performance brought about by volume-based procurement and slowdown in growth, and laid a solid foundation for the

		Company's medium- to long-term development strategy.
Net cash flows from operating activities – from the beginning of the year to the end of the Reporting Period	-231.72	Mainly due to the increase in investment in the Company's research and development capability to increase its market shares and competitiveness of products, the increase in sales cost to continuously expanding its market channels and rapidly increasing the sales volume of new products and the increase in accounts receivables.
Net profit attributable to shareholders of listed company after deducting nonrecurring profit or loss – this Reporting Period	-46.80	Mainly due to the increase in cost resulting from the rapid growth in the Company's sales volume since the implementation of volume-based procurement and the increase in research and development investment as a result of rapidly obtaining of certificates for new products.

2. Information of shareholders

(A) Total number of ordinary shareholders, preferred shareholders whose voting rights have been reinstated, and the shareholding of top ten shareholders

Unit: Share

Total number of ordinary shareholders at the end of the Reporting Period		17,119		Total number of shareholders of preferred shares with voting rights reinstated (if any)		Nil
Shareholding of top ten shareholders						
Name of shareholder	Nature of shareholder	Number of shares held	Shareholding percentage	Number of shares held subject to trading	Number of Shares subject to	Shares charged, tagged or frozen

			(%)	restriction s	trading restrict ions that include lending shares for securiti es financin g	Status of shares	Numb er
Shi Chunbao	Domestic natural person	114,840,685	29.88	113,685,435	0	None	0
Yue Shujun	Domestic natural person	95,447,900	24.84	95,447,900	0	None	0
HKSCC NOMINEES LIMITED	Foreign legal person	94,680,695	24.64	0	0	Unknown	0
Panmao (Shanghai) Investment Center (LLP) (磐茂 (上海)投資 中心(有限 合夥))	Domestic non-state- owned legal person	17,250,000	4.49	17,250,000	0	None	0
Lin Yiming	Domestic natural person	5,800,000	1.51	5,800,000	0	None	0
Sun Weiqi	Domestic natural person	4,416,665	1.15	4,416,665	0	None	0
Jin Jie	Domestic natural person	4,166,665	1.08	4,166,665	0	None	0

Huatai Chunli Medical Family No. 1 the collective asset management plan for the shareholding of staff on Technology Innovation Board	Others	3,615,601	0.94	3,615,601	0	None	0
Huang Dong	Domestic natural person	2,533,335	0.66	2,533,335	0	None	0
Industrial and Commercial Bank of China Limited - China-Europe Medical and Health Hybrid Securities Investment Fund	Others	2,518,153	0.66	0	0	None	0
Shareholding of top ten shareholders not subject to trading restrictions							
Name of shareholder	Number of tradable shares held not subject to trading restrictions	Share class and number					
		Share class	Number				
HKSCC NOMINEES LIMITED	94,680,695	Overseas listed foreign shares	94,680,695				

Industrial and Commercial Bank of China Limited - China-Europe Medical and Health Hybrid Securities Investment Fund	2,518,153	RMB-denominated ordinary shares	2,518,153
Shi Chunbao	1,155,250	Overseas listed foreign shares	1,155,250
東方證券股份有限公司 (Dongfang Securities Co., Ltd.)—中庚價值先鋒股票型證券投資基金 (Zhong Geng Value Vanguard Stock Securities Investment Fund)	910,889	RMB-denominated ordinary shares	910,889
Ping An Bank Co. Ltd. —中庚價值靈動靈活配置混合型證券投資基金 (Zhong Geng Value Smart and Flexible Allocation Hybrid Securities Investment Fund)	801,323	RMB-denominated ordinary shares	801,323
Industrial Bank Co., Ltd. —廣發穩鑫保本混合型證券投資基金 (Guangfa Wenxin Capital Guaranteed Hybrid Securities Investment Fund)	516,274	RMB-denominated ordinary shares	516,274
Hong Kong Securities Clearing Company Limited	397,699	RMB-denominated ordinary shares	397,699
China Minsheng Banking Corp., Ltd. —景順長城醫療健康混合型證券投資基金 (Jingshun Great Wall Medical and Health Hybrid Securities Investment Fund)	382,203	RMB-denominated ordinary shares	382,203
China Bohai Bank Co., Ltd. —中信建投醫改靈活配置混合型證券投資基金 (China Securities Healthcare Reform Flexible Allocation Hybrid Securities Investment Fund)	346,313	RMB-denominated ordinary shares	346,313
Gao Jue	280,000	RMB-denominated ordinary shares	280,000

Description of connected relationship or acting in concert of the above shareholders	Among the above top ten shareholders, Shi Chunbao and Yue Shujun are couple, Panmao (Shanghai) Investment Center (LLP) and Panxin (Shanghai) Investment Center (LLP) are two institutional shareholders, wholly-owned subsidiaries of CITICPE, and are associates of each other; Apart from the above connected relationships, the Company does not receive any statement from the other shareholders regarding the existence of connected relationship or agreement of acting-in-concert.
Description on participation in margin financing and securities lending and lending shares for securities financing by top ten shareholders and top ten shareholders not subject to trading restrictions (if any)	None

Note: Shares held by HKSCC Nominees Limited are held on behalf of its clients. As the relevant rules of the Hong Kong Stock Exchange do not require clients to report whether the shares that they hold are pledged or frozen, HKSCC Nominees Limited is therefore unable to calculate or provide the number of shares that have been pledged or frozen. The number of shares held by HKSCC Nominees Limited shown is exclusive of the number of H shares held by Mr. Shi Chunbao, an actual controller of the Company.

Note: At the end of the Reporting Period, the number of shareholders of the Company's A share was 17,101 and the number of registered shareholders of H shares was 18.

3. Other notice

Other important information related to the operational conditions of the Company during the Reporting Period which requires the attention of the investors

☒Applicable ☐Not applicable

On 27 September 2022, the tender for volume-based procurement of orthopedic spinal consumables organized by the PRC government officially kicked off in Shanghai. On 30 September 2022, the Office of Joint Procurement for High-Value Medical Consumables Organized by the State (国家组织高值医用耗材联合采购办公室) announced the selection results, all of the eight categories of product series submitted by the Company were selected. According to notice, all districts of the alliance will execute the results starting from January to February 2023, with the exact date of execution to be decided by each district.

The implementation of volume-based procurement organized by the PRC government has enabled leading domestic enterprises to enlarge their market shares. As a leading orthopedic medical device enterprise, the Company will leverage its strengths to actively respond to national policies as well as timely monitor and analyze market dynamics of the State, provinces and cities, so as to actively push forward the establishment of

marketing network and further enlarge its market share. The Company will implement its strategic layout by focusing on the future.

4. Quarterly financial statements

(A) Type of auditor' s opinion

☐Applicable ☒Not applicable

(B) Financial statements

CONSOLIDATED BALANCE SHEET

30 September 2022

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2022	31 December 2021
Current assets:		
Monetary funds	1,068,402,017.35	1,736,493,995.38
Settlement reserve		
Placements with banks and non-bank financial institutions		
Held-for-trading financial assets	490,798,534.25	
Derivative financial assets		
Notes receivable	115,181,778.64	127,595,937.14
Accounts receivable	531,043,753.44	400,193,012.58
Accounts receivable financing		
Prepayment	24,599,038.29	7,656,146.95
Premium receivable		
Reinsurance premium receivables		
Reserves for reinsurance contract receivables		
Other receivables	4,571,372.57	4,489,954.17
Including: Interests receivables		
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	250,586,132.58	159,677,359.96
Contract assets		
Assets held-for-sale		
Non-current assets due within one year		

Other current assets	9,389,491.98	11,657,475.04
Total current assets	2,494,572,119.10	2,447,763,881.22
Non-current assets:		
Loans and advances to customers		
Debt investments		
Other debt investments		
Long-term receivables		
Long-term equity investments		
Other investments in equity instruments		
Other non-current financial assets		
Investment property		
Fixed assets	281,738,737.28	111,389,835.89
Construction in progress	166,895,321.83	281,558,992.24
Productive biological assets		
Oil & gas assets		
Right-of-use assets	2,258,826.75	1,798,726.19
Intangible assets	140,974,804.52	131,974,040.11
Development expenditures		
Goodwill		
Long-term prepayments		128,333.51
Deferred income tax assets	19,853,575.55	22,882,542.60
Other non-current assets	3,382,166.56	2,161,009.69
Total non-current assets	615,103,432.49	551,893,480.23
Total assets	3,109,675,551.59	2,999,657,361.45
Current liabilities:		
Short-term borrowings		
Borrowings from central banks		
Placements from banks and non-bank financial institutions		
Held-for-trading financial liabilities		
Derivative financial liabilities		
Notes payable		
Accounts payable	157,665,253.41	142,415,529.82
Advances received	7,200,438.10	6,992,973.01
Contract liabilities	79,870,156.22	59,540,669.01
Financial assets sold under repurchase agreement		
Deposits and placements from peers		
Brokerage for trading securities		
Brokerage for underwriting		

securities		
Employee remuneration payable	24,901,550.00	46,267,095.42
Taxes payable	13,806,081.68	32,302,495.73
Other payables	69,098,808.41	75,055,164.38
Including: Interests payable		
Dividends payable		
Handling fee and commission payables		
Reinsurance premium payables		
Held-for-sale liabilities		
Non-current liabilities due within one year	852,832.72	1,226,469.52
Other current liabilities	45,822,220.97	75,818,491.35
Total current liabilities	399,217,341.51	439,618,888.24
Non-current liabilities:		
Reserves for insurance contracts		
Long-term borrowings		
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	466,952.13	
Long-term payables		
Long-term employee remuneration payable		
Estimated liabilities		
Deferred income	82,988,323.64	85,558,271.60
Deferred income tax liabilities	5,314,767.61	5,402,815.13
Other non-current liabilities		
Total non-current liabilities	88,770,043.38	90,961,086.73
Total liabilities	487,987,384.89	530,579,974.97
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	384,280,000.00	384,280,000.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital reserve	1,051,228,272.24	1,051,228,272.24
Less: treasury shares	7,140,352.41	
Other comprehensive income		
Specific reserve		
Surplus reserve	124,721,689.87	124,721,689.87
General reserve		
Undistributed profits	1,068,598,557.00	908,847,424.37

Total equity attributable to owners (or equity attributable to shareholders) of the parent company	2,621,688,166.70	2,469,077,386.48
Minority interests		
Total owners' equity (or shareholders' equity)	2,621,688,166.70	2,469,077,386.48
Total liabilities and owners' equity (or shareholders' equity)	3,109,675,551.59	2,999,657,361.45

Person in charge of the Company: Shi Wenling Person in charge for accounting affairs of the Company: Li Yumei Person in charge of the accounting department: Li Yumei

Consolidated income statement

January to September 2022

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2022 (January to September)	First three quarters of 2021 (January to September)
1. Total operating revenue	759,964,308.26	718,393,295.82
Including: Operating revenue	759,964,308.26	718,393,295.82
Interest income		
Premiums gained		
Income from handling fee and commission		
2. Total operating cost	550,512,366.06	485,734,423.65
Including: Operating cost	198,475,858.69	167,376,586.54
Interest expense		
Handling fee and commission expense		
Surrender value		
Net amount of compensation payout		
Net amount of insurance contracts reserves withdrew		
Policy dividend payment		
Reinsurance Expenses		
Taxes and surcharge	8,754,270.79	6,500,389.98
Selling expenses	230,167,966.03	233,798,001.06

Administrative expenses	24,677,613.84	21,391,625.40
Research and development expenses	105,014,400.73	65,183,009.37
Financial expenses	-16,577,744.02	-8,515,188.70
Including: Interest expenses		
Interest income	11,813,567.92	8,346,181.58
Add: Other gains	22,173,040.13	15,452,912.54
Investment income (losses are presented as “-”)	6,561,150.69	
Including: Investment income from associates and joint ventures		
Gains from derecognition of financial assets measured at amortised cost		
Foreign exchange gains (losses are presented as “-”)		
Net profit on hedging exposure (losses are presented as “ - ”)		
Gains on changes of fair value (losses are presented as “ - ”)	6,539,410.97	
Loss on credit impairment (losses are presented as “ - ”)	-10,513,769.24	-12,255,646.32
Loss on asset impairment (losses are presented as “ - ”)	-2,912,398.06	-637,716.35
Gains on disposal of assets (losses are presented as “ - ”)	25,305.66	14,856.74
3. Operating profit (losses are presented as “ - ”)	231,324,682.35	235,233,278.78
Add: Non-operating income	44,034.43	74,935.16

Less: Non-operating expenses	2,294,278.39	236,215.51
4. Gross profit (total losses are presented as “ - ”)	229,074,438.39	235,071,998.43
Less: income tax expenses	19,366,905.76	30,896,788.20
5. Net profit (net losses are presented as “ - ”)	209,707,532.63	204,175,210.23
(A) Classified by continuity of operation:		
1. Net profit for continuing operation (net losses are presented as “ - ”)	209,707,532.63	204,175,210.23
2. Net profit for ceased operation (net losses are presented as “ - ”)		
(B) Classified by ownership:		
1. Net profit attributable to the shareholders of the parent company (net losses are presented as “ - ”)	209,707,532.63	204,175,210.23
2. Non-controlling shareholders' profit or loss (net losses are presented as “ - ”)		
6. Net other comprehensive income after tax		
(I) Net other comprehensive income after tax attributable to the owners of the parent company		
1. Other comprehensive income that cannot be reclassified into profit or loss		
(1) Changes in remeasurement on defined benefit plan		
(2) Other comprehensive income that		

cannot be transferred to profit and loss under equity method		
(3) Fair value change on other investments in equity instruments		
(4) Fair value change on credit risk of the enterprise		
2. Other comprehensive income that will be reclassified into profit or loss		
(1) Other comprehensive income that can be transferred to profit and loss under equity method		
(2) Fair value change on other debt investments		
(3) Amounts of financial assets reclassified into other comprehensive income		
(4) Provision on credit impairment on other debt investments		
(5) Reserves of cash flow hedging		
(6) Translation difference on financial statements denominated in foreign currencies		
(7) Others		
(II) Net other comprehensive income after tax attributable to non-controlling shareholders		
7. Total comprehensive income	209,707,532.63	204,175,210.23
(A) Total comprehensive income attributable to the	209,707,532.63	204,175,210.23

owners of the parent company		
(B) Total comprehensive income attributable to non-controlling shareholders		
8. Earnings per share:		
(A) Basic earnings per share (yuan/share)	0.55	0.59
(B) Diluted earnings per share (yuan/share)	0.55	0.59

For business combination under common control conducted during the current period, the acquiree achieved a net profit of RMB 0 before the combination; the acquiree achieved a net profit of RMB 0 during the previous period.

Person in charge of the Company: Shi Wenling Person in charge for accounting affairs of the Company: Li Yumei Person in charge of the accounting department: Li Yumei

Consolidated cash flow statement

January to September 2022

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2022 (January to September)	First three quarters of 2021 (January to September)
1. Cash flows from operating activities:		
Cash receipts from sale of goods and rendering of services	643,963,252.24	622,028,881.77
Net increase in the amounts of deposits from customers and placements from peers		
Net increase in amounts due to central banks		
Net increase in placements from other financial institutions		
Cash received from the premium of original insurance contract		
Net cash received from reinsurance business		
Net increase in policyholder deposits and amount for investment		
Cash received from interest, handling fee and commission		

Net increase in placements from banks and non-bank financial institutions		
Net increase in capital on business repurchased		
Net cash received on securities dealing agency services		
Receipts of tax refund		
Other cash receipts related to operating activities	31,641,477.11	13,584,081.49
Subtotal of cash inflow from operating activities	675,604,729.35	635,612,963.26
Cash payments for goods purchased and services received	231,644,127.24	129,440,905.18
Net increase in loans and advances from customers		
Net increase in amounts deposited in central bank and peers		
Cash payment on compensation payout in original insurance contract		
Net increase in placements with banks and non-bank financial institutions		
Cash payment on interest, handling fee and commission		
Cash payment for policy dividend		
Cash paid to and on behalf of employees	146,133,791.96	108,955,264.21
Taxes paid	87,164,303.47	116,203,897.09
Other cash payments related to operating activities	287,031,448.40	223,035,804.00
Subtotal cash outflow from operating activities	751,973,671.07	577,635,870.48
Net cash flows from operating activities	-76,368,941.72	57,977,092.78
2. Cash flows from investing activities:		
Cash received from disinvestments	1,538,000,000.00	
Cash received from return on investments	12,302,027.41	
Net cash received from the disposal of fixed assets, intangible assets and other long-term assets	63,500.00	34,000.00
Net cash received from the disposal		

of subsidiaries and other business units		
Other cash receipts related to investing activities		6,752,876.71
Subtotal of cash inflow from investing activities	1,550,365,527.41	6,786,876.71
Cash paid for acquiring fixed assets, intangible assets and other long-term assets	57,315,502.70	183,326,709.89
Cash payments for investments	2,028,000,000.00	
Net increase in pledged loans		
Net cash payments for acquisitions of subsidiaries and other business units		
Other cash payments related to investing activities		
Subtotal of cash outflow from investing activities	2,085,315,502.70	183,326,709.89
Net cash flows from investing activities	-534,949,975.29	-176,539,833.18
3. Cash flows from financing activities:		
Cash received from investments		
Including: cash received by subsidiaries from non-controlling shareholders' investments		
Cash received from borrowings		
Other cash receipts related to financing activities		
Subtotal of cash inflow from financing activities		
Cash repayment of debts		
Cash paid for distribution of dividends, profits or for interest expenses	50,040,811.74	
Including: dividends and profit paid by subsidiaries to non-controlling shareholders		
Other cash payments related to financing activities	8,791,201.88	1,685,045.25
Subtotal of cash outflow from financing activities	58,832,013.62	1,685,045.25
Net cash flows from financing activities	-58,832,013.62	-1,685,045.25

4. Effect of foreign exchange rate changes on cash and cash equivalents	2,058,952.60	-661,404.62
5. Net increase in cash and cash equivalents	-668,091,978.03	-120,909,190.27
Add: Opening balance of cash and cash equivalents	1,736,493,995.38	690,116,229.19
6. Closing balance of cash and cash equivalents	1,068,402,017.35	569,207,038.92

Person in charge of the Company: Shi Wenling Person in charge for accounting affairs of the Company: Li Yumei Person in charge of the accounting department: Li Yumei

Adjustments to the financial statements at the beginning of the year of the first implementation due to the first implementation of the new accounting standards or interpretation of accounting standards since 2022

☐Applicable ☒Not applicable

The Board of Directors of Beijing Chunlizhengda Medical Instruments Co., Ltd.
26 October 2022